Announcements & Publications

September 21, 2021
Goldilocks Therapeutics, Inc. was awarded a $300K Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) entitled: “Efficacy and pharmacokinetic assessment of renal-targeted therapy in a pig model of cisplatin induced acute kidney injury.” This work is designed to provide the first large-animal proof-of-concept showing efficacy using the Company’s mesoscale nanoparticle (MNP) platform. It is estimated that over 100,000 cancer patients in the U.S. receive cisplatin annually; about 30% of these individuals develop AKI, which interferes with their ability to receive optimal chemotherapy. Goldilocks’ Principal Investigator for this grant is Associate Director of Research Chintan Kapadia, Ph.D. under Award Number R43DK131669.

September 25, 2020
Efficacy data on the use of an MNP version of a renalase agonist peptide in treating cisplatin-induced chronic kidney disease in mice presented at the New York Academy of Sciences “Drug Discovery for Remission of Chronic Kidney Disease” conference

September 17, 2020
Research article published showing that MNP-encapsulated NEMO binding peptide decreases ischemic acute kidney injury in a mouse model